Rhythm (RYTM) Fundamental Analysis: Revenue, Earnings & Valuation

1.28 / 10

Underperform

Fundamentally, Rhythm Pharma underperforms with a 1.3/10 score. Inventory turnover and cost‑of‑sales ratios are strong, but PB‑ROE, Asset‑MV and revenue‑MV are weak, indicating poor valuation and asset efficiency.

Analysis Checks(7/10)

Revenue-MV

Value-2.53

Score1/3

Weight39.79%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value45.83

Score2/3

Weight1.10%

1M Return0.13%

Inventory turnover ratio

Value0.88

Score3/3

Weight-7.87%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value50.41

Score2/3

Weight3.10%

1M Return0.36%

PB-ROE

Value13.03

Score0/3

Weight26.99%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value0.29

Score3/3

Weight7.01%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-9.29%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value45.83

Score2/3

Weight0.45%

1M Return0.05%

Cost of sales ratio (%)

Value10.27

Score3/3

Weight2.32%

1M Return0.26%

Asset-MV

Value-0.55

Score0/3

Weight36.41%

1M Return4.00%

Is RYTM undervalued or overvalued?

RYTM scores 1.28/10 on fundamentals and holds a Premium valuation at present. Backed by its -92.93% ROE, -103.57% net margin, -29.41 P/E ratio, 21.99 P/B ratio, and 28.34% earnings growth, these metrics solidify its Underperform investment rating.